恩杂鲁胺和帕博利珠单抗治疗进展后的疗法：在新治疗格局中探索转移性尿路上皮癌的二线治疗选择
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
作者信息
Brown Jason R, Koshkin Vadim S
机构信息
Seidman Cancer Center, University Hospitals Cleveland, Cleveland, OH, USA; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
出版信息
Eur Urol Focus. 2024 Mar;10(2):231-233. doi: 10.1016/j.euf.2024.05.011. Epub 2024 May 25.
There is no clear standard-of-care treatment for patients with metastatic urothelial carcinoma following progression on enfortumab vedotin and pembrolizumab, although multiple regimens are available, including platinum-based chemotherapy, sacituzumab govitecan, and erdafitinib for selected patients. Clinical trials will be important in informing decisions on the best treatment.
对于接受恩杂鲁胺和帕博利珠单抗治疗后病情进展的转移性尿路上皮癌患者，目前尚无明确的标准治疗方案，尽管有多种治疗方案可供选择，包括铂类化疗、戈沙妥珠单抗以及针对特定患者的厄达替尼。临床试验对于指导最佳治疗决策至关重要。
Zotero 插件